Tag: NYSE: PTN

Business

Palatin Technologies, Inc. (NYSE: PTN) Announces Optimistic End-of-Phase 2 Conference with FDA on PL9643 for the Management of Dry Eye Disease

Palatin Technologies, Inc. (NYSE: PTN) today announced the conclusion of an End-of-Phase 2 (EOP2) conference with the U.S. Food and Drug Administration (FDA) for PL9643 for the management of dry eye disease (DED). Conference latitude comprised all features of PL9643’s progress plan The EOP2 conference possibility included all facets of […]